MXPA00010241A - Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. - Google Patents
Composicion farmaceutica que comprende el factor viii y liposomas neutrales..Info
- Publication number
- MXPA00010241A MXPA00010241A MXPA00010241A MXPA00010241A MXPA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A MX PA00010241 A MXPA00010241 A MX PA00010241A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- protein
- factor viii
- colloidal particles
- polypeptide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion farmaceutica para administracion parenteral que comprende una cantidad terapeuticamente efectiva de una proteina o polipeptido y particulas coloidales substancialmente neutrales. Las particulas comprenden aproximadamente 1-20 por ciento en mol de un derivado lipidico anfipatico con un polimero hidrofilico biocompatible el cual no porta substancialmente cargas netas. La proteina o polipeptido es capaz de enlazar externamente las particulas coloidales, o es capaz de enlazar polietilenglicol, y no se encapsula en las particulas coloidales. Una proteina preferida es el factor VIII, cuya vida media se prolonga y que se protege de los anticuerpos inhibidores de suero al inyectarse como un componente de la composicion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12422498 | 1998-04-27 | ||
PCT/IL1999/000217 WO1999055306A1 (en) | 1998-04-27 | 1999-04-23 | Pharmaceutical composition comprising factor viii and neutral liposomes |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00010241A true MXPA00010241A (es) | 2004-09-06 |
Family
ID=11071435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA00010241A MXPA00010241A (es) | 1998-04-27 | 1999-04-23 | Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. |
Country Status (12)
Country | Link |
---|---|
US (2) | US6593294B1 (es) |
EP (1) | EP1079805B1 (es) |
JP (1) | JP4545928B2 (es) |
AT (1) | ATE283034T1 (es) |
AU (1) | AU747391B2 (es) |
BR (1) | BR9909978A (es) |
CA (1) | CA2329768C (es) |
DE (1) | DE69922189T2 (es) |
ES (1) | ES2233036T3 (es) |
MX (1) | MXPA00010241A (es) |
PT (1) | PT1079805E (es) |
WO (1) | WO1999055306A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7625584B2 (en) * | 2000-11-30 | 2009-12-01 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
US8110218B2 (en) | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
US20020132982A1 (en) * | 2000-11-30 | 2002-09-19 | Balasubramanian Sathyamangalam V. | AHF associated dispersion system and method for preparation |
AU2003241598B2 (en) * | 2002-07-02 | 2009-11-05 | Nanotx Corp. | Radiolabeled compounds and liposomes and their methods of making and using the same |
US7351688B2 (en) * | 2003-02-05 | 2008-04-01 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein formulations |
PL1633440T3 (pl) * | 2003-04-15 | 2008-12-31 | Opperbas Holding Bv | Kompozycja farmaceutyczna zawierająca białka i/lub polipeptydy oraz cząstki koloidalne |
US20050069578A1 (en) * | 2003-08-05 | 2005-03-31 | Balasubramanian Sathyamangalam V. | Reconstitution medium for protein and peptide formulations |
US20070003607A1 (en) * | 2003-09-02 | 2007-01-04 | Vibhudutta Awasthi | Neutral liposome-encapsulated compounds and methods of making and using thereof |
US7208174B2 (en) * | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
US8182834B2 (en) * | 2004-01-23 | 2012-05-22 | Camurus Ab | Ternary non-lamellar lipid compositions |
LT2363414T (lt) | 2004-11-12 | 2022-10-25 | Bayer Healthcare Llc | Fviii modifikacija, nukreipta į tam tikrą vietą |
JP2008536874A (ja) * | 2005-04-15 | 2008-09-11 | ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム | 中性脂質組成物によるsiRNAの送達 |
JP2008544990A (ja) * | 2005-06-29 | 2008-12-11 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 低免疫原性蛋白質−脂質複合体に関する組成物および方法 |
US7662405B2 (en) | 2005-08-09 | 2010-02-16 | The Research Foundation Of State University Of New York | Compositions and methods of preparation of liposomal microparticulate IL-12 |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
EP2007357B1 (en) | 2006-03-30 | 2016-11-09 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
US7875288B2 (en) | 2006-03-30 | 2011-01-25 | The Research Foundation Of State University Of New York | Method for treating blood coagulation disorders |
EP2101821B1 (en) * | 2006-12-15 | 2014-08-13 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
CA2673459C (en) | 2006-12-22 | 2016-09-13 | Stefan Schulte | Modified coagulation factors with prolonged in vivo half-life |
RU2528855C2 (ru) | 2008-06-24 | 2014-09-20 | Цсл Беринг Гмбх | Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения |
CN104274866B (zh) | 2008-07-14 | 2016-08-24 | 波利皮得有限公司 | 持续释放药物载体组合物 |
WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
CN105126179B (zh) | 2009-07-14 | 2018-09-25 | 波利皮得有限公司 | 持续释放药物载体组合物 |
WO2011025893A1 (en) | 2009-08-28 | 2011-03-03 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and devices for production of gas-filled microbubbles |
US20130028959A1 (en) | 2009-12-16 | 2013-01-31 | Massachusetts Institute Of Technology | Liposomes for Preventing the Spread of HIV |
EP2512588A4 (en) | 2009-12-16 | 2014-06-04 | Univ Columbia | METHODS, DEVICES, AND SYSTEMS FOR DELIVERY OF ULTRASOUND-DEMARTED MEDICATION |
CA2783001C (en) | 2010-01-19 | 2017-12-12 | Polypid Ltd. | Sustained-release nucleic acid matrix compositions |
US8637448B2 (en) * | 2010-09-14 | 2014-01-28 | University Of Rochester | Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface |
DE102010043733A1 (de) | 2010-11-10 | 2012-05-10 | Oxprotect Gmbh | Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen |
WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
BR112016030950A2 (pt) | 2014-07-02 | 2018-03-27 | Csl Ltd | polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira. |
GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
US11155601B2 (en) | 2015-03-06 | 2021-10-26 | CSL Behring Lengnau AG | Modified von Willebrand factor having improved half-life |
MX2017014503A (es) | 2015-05-22 | 2018-08-01 | CSL Behring Lengnau AG | Polipeptidos de factor de von willebrand truncado para tratar hemofilia. |
EP3298036B1 (en) | 2015-05-22 | 2022-04-06 | CSL Behring Lengnau AG | Methods for preparing modified von willebrand factor |
GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
CA3010720A1 (en) | 2016-01-07 | 2017-07-13 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
CA3008448A1 (en) | 2016-01-07 | 2017-07-13 | Csl Behring Recombinant Facility Ag | Mutated von willebrand factor |
WO2017220099A1 (en) | 2016-06-24 | 2017-12-28 | Statens Serum Institut | Adjuvants with modified drainage properties |
WO2018005657A1 (en) * | 2016-06-28 | 2018-01-04 | Verily Life Sciences Llc | Serial filtration to generate small cholesterol-containing liposomes |
CN109922824A (zh) | 2016-11-11 | 2019-06-21 | 康诺贝林伦瑙有限公司 | 用于治疗血友病的截短的冯维勒布兰德因子多肽 |
JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7900459A (nl) | 1979-01-19 | 1980-07-22 | Hendrik Coenraad Hemker Prof D | Farmaceutisch preparaat en werkwijze ter bereiding daarvan. |
JPS56127307A (en) * | 1980-03-11 | 1981-10-06 | Green Cross Corp:The | Blood-coagulation factor 8 pharmaceutical for oral administration |
US4348384A (en) | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
AU7217891A (en) * | 1990-02-13 | 1991-09-03 | Oxford Virology Plc | Therapeutic agents, and intermediates for the synthesis thereof |
US6326353B1 (en) | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
-
1999
- 1999-04-23 WO PCT/IL1999/000217 patent/WO1999055306A1/en active IP Right Grant
- 1999-04-23 BR BR9909978-0A patent/BR9909978A/pt not_active Application Discontinuation
- 1999-04-23 EP EP99916022A patent/EP1079805B1/en not_active Expired - Lifetime
- 1999-04-23 AT AT99916022T patent/ATE283034T1/de active
- 1999-04-23 PT PT99916022T patent/PT1079805E/pt unknown
- 1999-04-23 DE DE69922189T patent/DE69922189T2/de not_active Expired - Lifetime
- 1999-04-23 AU AU34414/99A patent/AU747391B2/en not_active Ceased
- 1999-04-23 US US09/673,412 patent/US6593294B1/en not_active Expired - Lifetime
- 1999-04-23 ES ES99916022T patent/ES2233036T3/es not_active Expired - Lifetime
- 1999-04-23 JP JP2000545506A patent/JP4545928B2/ja not_active Expired - Fee Related
- 1999-04-23 MX MXPA00010241A patent/MXPA00010241A/es active IP Right Grant
- 1999-04-23 CA CA002329768A patent/CA2329768C/en not_active Expired - Fee Related
-
2002
- 2002-12-26 US US10/327,970 patent/US6930087B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2329768A1 (en) | 1999-11-04 |
PT1079805E (pt) | 2005-03-31 |
US6930087B2 (en) | 2005-08-16 |
ATE283034T1 (de) | 2004-12-15 |
JP2002512947A (ja) | 2002-05-08 |
WO1999055306A1 (en) | 1999-11-04 |
EP1079805A1 (en) | 2001-03-07 |
EP1079805B1 (en) | 2004-11-24 |
DE69922189D1 (de) | 2004-12-30 |
US6593294B1 (en) | 2003-07-15 |
ES2233036T3 (es) | 2005-06-01 |
CA2329768C (en) | 2008-06-10 |
US20030134778A1 (en) | 2003-07-17 |
AU747391B2 (en) | 2002-05-16 |
JP4545928B2 (ja) | 2010-09-15 |
BR9909978A (pt) | 2000-12-26 |
DE69922189T2 (de) | 2005-11-10 |
AU3441499A (en) | 1999-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA00010241A (es) | Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. | |
CA2155005A1 (en) | Pharmaceutical Compositions Containing Bactericidal Permeability Increasing Protein and a Surfactant | |
WO2002048183A3 (en) | Compositions of peptide crystals | |
DE69312947D1 (de) | Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe | |
FI971776A (fi) | Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi | |
AU7678196A (en) | Methods and compositions for the delivery of monomeric proteins | |
EP0993831A3 (en) | Compounds and compositions for delivering active agents | |
AU6726698A (en) | Use of interleukin-15 | |
AU6819294A (en) | Oral drug delivery compositions and methods | |
FI962154A0 (fi) | Koostumus terapeuttisten tuotteiden in vivo valmistusta varten | |
IL100731A0 (en) | Mixed specificity fusion protein and pharmaceutical composition containing it | |
IS5087A (is) | Stöðugar interferónlyfjablöndur á vökvaformi | |
AU2272097A (en) | Drug delivery compositions suitable for intravenous injection | |
WO1997010851A3 (en) | Nucleic acid delivery vehicle | |
EP0422125A4 (en) | Platelet blocking peptides | |
AU7683296A (en) | Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them | |
AU2975899A (en) | Colonic delivery of protein or peptide compositions | |
WO2001083783A3 (en) | In vivo loading of mhc | |
PT1633440E (pt) | Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais | |
IL128329A0 (en) | Pharmaceutical composition of hedgehog proteins and use thereof | |
WO2001066574A3 (en) | Cryptococcal mannoproteins or equivalents thereof for use in modulating neutrophil migration | |
MX9705082A (es) | Composiciones para el suministro de antigenos. | |
WO2000071573A3 (en) | Immunogenic peptides derived from mage and the use thereof | |
WO2003087329A3 (en) | Targeted cytocidal virionoids for antiangiogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights | ||
PD | Change of proprietorship |
Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED.* |
|
PD | Change of proprietorship |
Owner name: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED.* |